Rituximab is highly effective for pure red cell aplasia  	and post-transplant lymphoproliferative disorder after unrelated  	hematopoietic stem cell transplantation

Anna Kopińska; Grzegorz Helbig; Andrzej Frankiewicz; Iwona Grygoruk-Wiśniowska; Sławomira Kyrcz-Krzemień

doi:10.5114/wo.2012.29287

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2012
vol. 16

Send email

Copy url:

abstract:

Case report

Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation

Anna Kopińska

,

Grzegorz Helbig

,

Andrzej Frankiewicz

,

Iwona Grygoruk-Wiśniowska

,

Sławomira Kyrcz-Krzemień

Wspolczesna Onkol 2012; 16 (3): 215–217

DOI: https://doi.org/10.5114/wo.2012.29287

Online publish date: 2012/07/06

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Kopińska A, Helbig G, Frankiewicz A, Grygoruk-Wiśniowska I, Kyrcz-Krzemień S. Rituximab is highly effective for pure red cell aplasia  	and post-transplant lymphoproliferative disorder after unrelated  	hematopoietic stem cell transplantation. Contemporary Oncology/Współczesna Onkologia. 2012;16(3):215-217. doi:10.5114/wo.2012.29287.

APA

Kopińska, A., Helbig, G., Frankiewicz, A., Grygoruk-Wiśniowska, I.,  & Kyrcz-Krzemień, S. (2012). Rituximab is highly effective for pure red cell aplasia  	and post-transplant lymphoproliferative disorder after unrelated  	hematopoietic stem cell transplantation. Contemporary Oncology/Współczesna Onkologia, 16(3), 215-217. https://doi.org/10.5114/wo.2012.29287

Chicago

Kopińska, Anna, Grzegorz Helbig, Andrzej Frankiewicz, Iwona Grygoruk-Wiśniowska,  and Sławomira Kyrcz-Krzemień. 2012. "Rituximab is highly effective for pure red cell aplasia  	and post-transplant lymphoproliferative disorder after unrelated  	hematopoietic stem cell transplantation". Contemporary Oncology/Współczesna Onkologia 16 (3): 215-217. doi:10.5114/wo.2012.29287.

Harvard

Kopińska, A., Helbig, G., Frankiewicz, A., Grygoruk-Wiśniowska, I.,  and Kyrcz-Krzemień, S. (2012). Rituximab is highly effective for pure red cell aplasia  	and post-transplant lymphoproliferative disorder after unrelated  	hematopoietic stem cell transplantation. Contemporary Oncology/Współczesna Onkologia, 16(3), pp.215-217. https://doi.org/10.5114/wo.2012.29287

MLA

Kopińska, Anna et al. "Rituximab is highly effective for pure red cell aplasia  	and post-transplant lymphoproliferative disorder after unrelated  	hematopoietic stem cell transplantation." Contemporary Oncology/Współczesna Onkologia, vol. 16, no. 3, 2012, pp. 215-217. doi:10.5114/wo.2012.29287.

Vancouver

Kopińska A, Helbig G, Frankiewicz A, Grygoruk-Wiśniowska I, Kyrcz-Krzemień S. Rituximab is highly effective for pure red cell aplasia  	and post-transplant lymphoproliferative disorder after unrelated  	hematopoietic stem cell transplantation. Contemporary Oncology/Współczesna Onkologia. 2012;16(3):215-217. doi:10.5114/wo.2012.29287.

PlumX metrics:

Pure red cell aplasia (PRCA) and post-transplant lymphoproliferative disorder (PTLD) constitute rare complications after allogeneic hematopoietic stem cell transplantation (AlloHSCT). The incidence of EBV-PTLD is above 1%, but it may increase in patients with well-known risk factors such as EBV seronegativity at the time of transplantation,

T-cell depletion of donor grafts, HLA mismatch and use of antithymocyte globulin (ATG) for prophylaxis of graft

versus host disease. The risk factors for PRCA were defined and they include:

1) elevated post-transplant anti-donor

isohemagglutinin titers, 2) reduced-in-

tensity conditioning before transplant,

3) the presence of anti-A agglutinin and 4) ciclosporin for graft versus host disease (GVHD) prophylaxis and 5) transplant from sibling donor. The anti-CD20 monoclonal antibody rituximab remains the first line treatment for PTLD following AlloHSCT, but its efficacy in PRCA is limited. Reduction of immunosuppression is also strongly advised. This is the first report on an adult patient who simultaneously developed PRCA and PTLD after ABO-mismatched AlloHSCT. The early introduction of rituximab resulted in prompt resolution of clinical symptoms with subsequent full recovery.

keywords:

Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation

Anna Kopińska , Grzegorz Helbig , Andrzej Frankiewicz , Iwona Grygoruk-Wiśniowska , Sławomira Kyrcz-Krzemień

allogeneic hematopoietic stem cell transplantation, pure red cell aplasia, post-transplant lymphoproliferative disorder, rituximab

Anna Kopińska

,

Grzegorz Helbig

,

Andrzej Frankiewicz

,

Iwona Grygoruk-Wiśniowska

,

Sławomira Kyrcz-Krzemień